Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00896324 · ClinicalTrials.gov registry record · NA

Intellectual Impairment in Women With Breast Cancer

A NA study of Breast Cancer, sponsored by Stanford University.

Completed
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT00896324: Completed NA study of Breast Cancer, sponsored by Stanford University.

NCT00896324 is a NA study of Breast Cancer that has completed, run by Stanford University. The registered enrollment target is 50 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00896324, a NA study of Breast Cancer, has completed, sponsored by Stanford University.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Breast cancer and its treatment may cause changes in a patient's ability to think, learn, and remember. Gathering information about a woman's genes, brain function, and personal history may help doctors learn more about the disease and plan the best treatment. PURPOSE: 1. To determine changes in brain function that occur following breast cancer chemotherapy. 2. To gain further understanding of the individual differences in brain function changes and recovery based on demographic, medical and treatment variables.

Primary Outcome

Evaluation of efficacy of executive function (EF) will be done via Neuropsychological and Neuroimaging (using functional MRI) assessments. Measurements of executive function, memory, processing speed, attention, visual-spatial processing and language will be compared before and after 6 weeks of cognitive rehabilitation program. Neuropsychological assessment and neuroimaging assessment changes will be compared from baseline to post-assessment in the intervention groups. Mixed effects approach and

Conditions Studied

Interventions

  • BEHAVIORAL Cognitive Rehabilitation
  • BEHAVIORAL Active Neurofeedback Training
  • BEHAVIORAL Neurofeedback Training (placebo / Sham)

Study Locations (1)

California

  • Stanford University School of Medicine - Stanford

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2009-01-12
Est. Completion 2013-06
Phase NA
Stanford University

1,744 total trials

What the finished NCT00896324 record still lists

NCT00896324 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cognitive Rehabilitation is the first listed.

NCT00896324 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT00896324 about?

NCT00896324 is a clinical study titled "Intellectual Impairment in Women With Breast Cancer". RATIONALE: Breast cancer and its treatment may cause changes in a patient's ability to think, learn, and remember. Gathering information about a woman's genes, brain function, and personal history may help doctors learn more about the disease and plan the best treatment. PURPOSE: 1. To determine c...

What is the current status of trial NCT00896324?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2009-01-12. Estimated completion is 2013-06.

What conditions does trial NCT00896324 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00896324?

The interventions under investigation include: Cognitive Rehabilitation (BEHAVIORAL), Active Neurofeedback Training (BEHAVIORAL), Neurofeedback Training (placebo / Sham) (BEHAVIORAL).

Who is sponsoring clinical trial NCT00896324?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00896324 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00896324's enrollment target sits among peer trials

50 789th of 1224 higher than 410 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00896324, the US trial registry maintained by the National Library of Medicine. NCT00896324 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.